Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: just another rotation as the cycle continues to roll up and down

July 30, 2019 8:32pm

Volume remains low while percentage movements stay truncated

Pre-open indications: 1 HIT and 4 MISS

As I skimmed the upside for a profitable day as the IBB (+0.90%) and the XBI (+1.51%) closed

We crave explanations because they give us an illusion of control.

Insight from what's a volatile climate; RMi outlines the preludes of a new week defining the mitigating factors of share pricing!

Markets and indexes:

The Dow closed down -23.33 points or -0.09% to 27,198.02;
The S&P closed down -7.79 points or -0.26% at 3,013.18;
The NASDAQ was down -19.72 or -0.24% to 8,273.61;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Tuesday the IBB closed up +0.90% while the XBI closed up +1.51%
Monday the IBB closed up +0.09% while the XBI closed down -0.22%
Friday the IBB closed up +1.07% while the XBI closed up +1.81%

Henry’omics:

Markets ramp and stocks fall after President Trump renewed his attacks on China, decreasing hope the two largest world economies will reach a trade deal. Investors also braced for a key announcement on U.S. monetary policy <CNBC>.

Market expectations point to a quarter-point rate cut. The Fed is set to deliver its decision Wednesday at 2 p.m. ET. Fed Chairman Jerome Powell is also scheduled to hold a news conference at 2:30 p.m. ET.

Pre-open post, “follow the bouncing share pricing as earnings season is upon us; while net losses lower per share pricing in two (2) (QURE and CRSP) releases and revenues lag estimates (CRSP) in one (1). We are back to expectation and anticipation.”

Tuesday’s advance/decline line scenario of 45 covered companies:

The open was negative with an A/D (A/D) line of 17/22 with 4 flats and 2 acquired;
The mid-day was positive with an A/D Line of 23/18 with 2 flats and 2 acquired;
The close was positive with an A/D Line of 26/18 and 1 flat and 2 acquired;

Pre-open indications: 1 HIT and 4 MISS

Pluristem (PSTI closed up +$0.18 – miss;
Solid Bioscience (SLDB closed down -$0.60 – hit;
CRSPER Therapeutics (CRSP closed down -$0.16 – miss;
Editas Medicine (EDIT closed up +$0.54 – miss;
ReNeuron (RENE.L ) closed down -$1.50 – miss;

Leading decliners were:

bluebird bio (BLUE -$3.78 after Monday’s -$2.92, Friday’s-$0.32, Thursday’s -$3.71,Wednesday’s +$3.40 and last Tuesday’s +$0.48;

uniQure (QURE -$2.07 after Monday’s -$3.53 and Friday’s -$1.35);
Sage Therapeutics (SAGE -$1.85 after Monday’s -$3.29);
Regenxbio (RGNX -$1.57 after Monday’s -$2.25);
ReNeuron (RENE.L -$1.50 after Monday’s +$5.00);

Tuesday’s incliners:

Alnylam Pharmaceuticals (ALNY +$2.35);
Ionis Pharmaceuticals (IONS +$1.20 after Monday’s +$0.40);
BioMarin Pharmaceuticals (BMRN +$1.18);
AxoGen (AXGN +$0.78);
BioLife Solutions (BLFS +$0.68)

The percentage (%) indicators:

Tuesday’s range of the 26 upside was +0.57% (ONCE) to +8.99% (SLDB) while the 18 downside ranged from -0.07% (ONVO) to -6% (ATHX);
Monday’s range of the 11 upside was +0.34% (EDIT) to +7.11% (PSTI) while the 31 downside ranged from -0.26% (CLLS) to -7.95% (CUR -$0.19);

Upside volume stats: to compare

Tuesday: 4 out of the 26 upside had higher than the 3 month average volume;
Monday: 2 out of the 11 upside had higher than the 3 month average volume;

Downside volume stats: NOTICE

Tuesday: 4 out of the 18 downside had higher than the 3 month average volume;
Monday: 6 out of the 31 downside had higher than the 3 month average volume;

1 flat – VSTM with 2 acquired (AST & OSIR) and the Spark Therapeutics’ (ONCE) acquisition by Roche still being delayed

July’s sessions and the beginning of Q3:

Tuesday closed POSITIVE with 18 decliners, 26 advancers, 1 flat and 2 acquired (AST & OSIR);

Monday closed NEGAIVE with 31 decliners, 11 advancers, 1 flat and 2 acquired (AST & OSIR);

Friday closed POSITIVE with 9 decliners, 32 advancers, 2 flats and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 32 decliners, 11 advancers, 0 flats and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 27 decliners, 14 advancers, 2 flats and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 23 decliners, 19 advancers, 1 flat and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 17 decliners, 24advancers, 2 flat and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 38 decliners, 4 advancers, 1 flat and 2 acquired (AST & OSIR);

Thursday closed POSITIVE with 14 decliners, 27 advancers, 2 flat and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 20 decliners, 23 advancers, 0 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 27 decliners, 15 advancers, 1 flat and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 15 decliners, 26 advancers, 2 flats and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 22 decliners, 21 advancers, 0 flats and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 26 decliners, 14 advancers, 3 flats and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 25 decliners, 16 advancers, 2 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 29 decliners, 13 advancers, 1 flat and 2 acquired (AST & OSIR);

Monday closed NEGATIVE with 24 decliners, 18 advancers, 1 flat and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 23 decliners, 19 advancers, 1 flat and 2 acquired (AST & OSIR);

Thursday was a holiday;

Wednesday closed POSITIVE with 10 decliners, 31 advancers, 2 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 30 decliners, 11 advancers, 2 flat and 2 acquired (AST & OSIR);

Monday closed NEGATIVE with 23 decliners, 19 advancers, 1 flat and 2 acquired (AST & OSIR);

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.